Identification of a 3-Gene Prognostic Index for Papillary Thyroid Carcinoma.

Autor:	Zhong LK; Department of General Surgery, Zhongshan City People's Hospital, Zhongshan, China., Deng XY; Thyroid, Vascular Surgery Department, Maoming People's Hospital, Maoming, China., Shen F; Department of Thyroid Surgery, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China., Cai WS; Department of Thyroid Surgery, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China., Feng JH; Department of Thyroid Surgery, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China., Gan XX; Department of Thyroid Surgery, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China., Jiang S; Reproductive Medicine Center, Boai Hsopital of Zhongshan, Zhongshan, China., Liu CZ; Department of General Surgery, Zhongshan City People's Hospital, Zhongshan, China., Zhang MG; Department of General Surgery, Zhongshan City People's Hospital, Zhongshan, China., Deng JW; Department of General Surgery, Zhongshan City People's Hospital, Zhongshan, China., Zheng BX; Department of General Surgery, Zhongshan City People's Hospital, Zhongshan, China., Xie XZ; Department of General Surgery, Zhongshan City People's Hospital, Zhongshan, China., Ning LQ; Department of General Surgery, Zhongshan City People's Hospital, Zhongshan, China., Huang H; Department of General Surgery, Zhongshan City People's Hospital, Zhongshan, China., Chen SS; Department of Intensive Care Medicine, Zhongshan City People's Hospital, Zhongshan, China., Miao JH; Department of General Surgery, Zhongshan City People's Hospital, Zhongshan, China., Xu B; Thyroid, Vascular Surgery Department, Maoming People's Hospital, Maoming, China.
Jazyk:	angličtina
Zdroj:	Frontiers in molecular biosciences [Front Mol Biosci] 2022 Mar 16; Vol. 9, pp. 807931. Date of Electronic Publication: 2022 Mar 16 (Print Publication: 2022).
DOI:	10.3389/fmolb.2022.807931
Abstrakt:	The accurate determination of the risk of cancer recurrence is a critical unmet need in managing thyroid cancer (TC). Although numerous studies have successfully demonstrated the use of high throughput molecular diagnostics in TC prediction, it has not been successfully applied in routine clinical use, particularly in Chinese patients. In our study, we objective to screen for characteristic genes specific to PTC and establish an accurate model for diagnosis and prognostic evaluation of PTC. We screen the differentially expressed genes by Python 3.6 in The Cancer Genome Atlas (TCGA) database. We discovered a three-gene signature Gap junction protein beta 4 (GJB4), Ripply transcriptional repressor 3 (RIPPLY3), and Adrenoceptor alpha 1B (ADRA1B) that had a statistically significant difference. Then we used Gene Expression Omnibus (GEO) database to establish a diagnostic and prognostic model to verify the three-gene signature. For experimental validation, immunohistochemistry in tissue microarrays showed that thyroid samples' proteins expressed by this three-gene are differentially expressed. Our protocol discovered a robust three-gene signature that can distinguish prognosis, which will have daily clinical application. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer XS declared a shared parent affiliation with the author(s) to the handling editor at the time of the review. (Copyright © 2022 Zhong, Deng, Shen, Cai, Feng, Gan, Jiang, Liu, Zhang, Deng, Zheng, Xie, Ning, Huang, Chen, Miao and Xu.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu